PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Inclusion Criteria

• •1. Male and female, aged 18-65;
• •2. newly-diagnosed high risk (aaipi 2-3 and aaipi 1 with large mass) DLBCL patients after autologous stem cell transplantation;
• •3. Laboratory tests (blood tests, liver and renal function) meet the following requirements:
• •1. Blood tests: white blood cell count ≥ 3.0 × 109 / L, absolute neutrophil count ≥ 1.5 × 109 / L, hemoglobin ≥ 90g / L, platelet ≥ 75 × 109 / L
• •2. Liver function: transaminase ≤ 2.5 × upper limit of normal value, bilirubin ≤ 1.5 × upper limit of normal value;
• •3. Renal function: serum creatinine 44-133 mmol / L;
• •4. The score of ECOG was 0-2;
• •5. The subject or his legal representative must provide written informed consent before the special examination or procedure of the study.